Precision BioSciences Initiates DMD Gene Editing Trial, Securing Early Momentum
Event summary
- Precision BioSciences has activated the first clinical trial site, Arkansas Children’s Hospital, for its Phase 1/2 FUNCTION-DMD study.
- The trial will enroll ambulatory DMD patients aged 2-7 with mutations between exons 45 and 55, representing approximately 60% of DMD cases.
- PBGENE-DMD utilizes Precision's ARCUS® platform to excise exons 45-55, aiming to restore a functional dystrophin protein.
- The program received Orphan Drug Designation in July 2025 and is eligible for a Priority Review Voucher (PRV) and Fast Track designation.
The big picture
Precision BioSciences' entry into the Duchenne muscular dystrophy gene editing space represents a significant development, as current treatment options offer limited functional benefit. The company's ARCUS platform aims to address the underlying genetic cause of DMD, potentially offering a more durable therapeutic effect. Securing the Priority Review Voucher (PRV) could expedite regulatory approval and significantly increase the program's value, but clinical success remains the primary driver.
What we're watching
- Enrollment Pace
- The speed of patient enrollment across additional trial sites will be a key indicator of trial efficiency and potential for timely data readouts, given the unmet need in DMD.
- Efficacy Signals
- Early data on dystrophin protein expression and functional outcomes will be critical to assess the therapeutic potential of PBGENE-DMD and its differentiated approach compared to microdystrophin therapies.
- PRV Utilization
- The potential to secure and utilize the Priority Review Voucher (PRV) will significantly impact the commercialization timeline and value proposition of PBGENE-DMD, contingent on positive clinical data.
Related topics